Pharmaceutical News

RSS

Mylan Pharmaceuticals receives final FDA report on Morgantown, W.Va., manufacturing facility

Mylan Inc. (Nasdaq: MYL) today announced that the U.S. Food and Drug Administration (FDA) has released its official and final report regarding the agency's review of allegations made in a July newspaper article concerning the company's Morgantown, W.Va., manufacturing facility.

14 Aug 2009

CVS Caremark announces results of 2009 Health IQ study

CVS Caremark (NYSE: CVS) announced today the results of its 2009 Health IQ study which examined consumer attitudes and behaviors around health care and prescription usage. Among its findings, the study underscores the need for expanded health care coverage along with cost savings realized by improving health care delivery.

13 Aug 2009

Sigma-Aldrich offers customizable synthetic extracellular matrix (ECM) for stem cell research

Sigma-Aldrich (Nasdaq: SIAL) today announced an agreement with Glycosan BioSystems for the sale of HyStem(TM), a fully customizable synthetic extracellular matrix (ECM) for stem cell research. HyStem offers researchers flexibility to tailor microenvironments for their cultured cells that mimic natural in vivo conditions, optimizing stem cell proliferation and differentiation. HyStem was developed by Glycosan BioSystems and will be sold by Sigma-Aldrich under a non-exclusive distribution agreement.

13 Aug 2009

Stanford researchers want FDA to require drug makers to state how new medications compare with similar, existing treatments

The labeling information that comes with prescription drugs tells you what’s known about the medication, but researchers from the Stanford University School of Medicine think it’s high time that the labeling tell you what isn’t known.

13 Aug 2009

Dynavax announces European development strategy for investigational adult hepatitis B vaccine in Europe

Dynavax Technologies Corporation (Nasdaq:DVAX) today announced that it has met with the European Medicines Evaluation Agency (EMEA) to discuss its plans for continued clinical development of HEPLISAVTM Phase 3 investigational adult hepatitis B vaccine in Europe.

12 Aug 2009

Bristol-Myers Squibb announces Hart-Scott-Rodino Review period for Medarex acquisition expired

Bristol-Myers Squibb Company (NYSE: BMY) announced today that the Hart-Scott-Rodino (HSR) review period for its tender offer for Medarex, Inc. (NASDAQ: MEDX) has expired.

12 Aug 2009

Nanoviricides herpes study discussed on CBS News report

NanoViricides, Inc. (OTC BB: NNVC.OB), reported today that the CBS affiliate TV station WBRZ interviewed Professor K. Gus Kousoulas , PhD, in which he explained the potential implications of the Company’s nanoviricides™ anti-Herpes drug candidates.

12 Aug 2009

Health Canada approves Multaq (Dronedarone) for atrial fibrillation

Sanofi-aventis Canada announced today that Multaq (dronedarone, 400 mg tablets) has received Health Canada approval for the treatment of patients with a history of, or current atrial fibrillation to reduce their risk of cardiovascular hospitalization due to this condition.

12 Aug 2009

Forest Labs and Astrazeneca to co-develop and commercialize ceftaroline

Forest Laboratories (NYSE:FRX) and AstraZeneca (NYSE:AZN) announced today they have entered into a definitive collaboration agreement to co-develop and commercialize ceftaroline in all markets outside the United States, Canada and Japan.

12 Aug 2009

Providers, patients in States face budget squeeze

Local newspapers report on health care issues in Delaware, Lousiana and Hawaii. In Delaware, The News Journal reports on a Medicaid-related agreement regarding the state and prescription drug costs.

12 Aug 2009

Schering-Plough announces agreement with Orchid Chemicals & Pharmaceuticals on generic forms of CLARINEX

Schering-Plough Corporation (NYSE: SGP) today announced an agreement with Orchid Chemicals & Pharmaceuticals Ltd. and Orgenus Pharma, Inc. ("Orchid"), related to the generic manufacturing of certain formulations of CLARINEX(R) (desloratadine).

12 Aug 2009

Ranbaxy receives approval to market Sumatriptan Succinate tablets

Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RLL has received final approval from the U.S. Food and Drug Administration to manufacture and market Sumatriptan Succinate Tablets, 25 mg (base), and 50 mg (base).

12 Aug 2009

Scientists discover how new drug kills roundworms

A PLoS Neglected Tropical Diseases study found how a new drug developed by scientists in China effectively kills roundworms – "a parasite that lurks in the intestines and which affects nearly two billion people in tropical countries," Reuters reports. "Roundworms are particularly harmful to children and pregnant women," Reuters writes.

12 Aug 2009

Labopharm submits response to FDA for formulation of the antidepressant trazodone

Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that it has submitted its response to the U.S. Food and Drug Administration's (FDA) complete response letter regarding the Company's novel formulation of the antidepressant trazodone.

11 Aug 2009

Teva announces approval of Oxaliplatin injection

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today announced U.S. Food and Drug Administration (FDA) approval and launch of Oxaliplatin Injection.

11 Aug 2009

Hospira launches generic version of Sanofi-Aventis' Eloxatin

Hospira, Inc. (NYSE: HSP) today announced U.S. Food and Drug Administration (FDA) approval and launch of oxaliplatin injection in the United States.

11 Aug 2009

Britain's first swine flu vaccine trials start

Britain's first swine flu vaccine trials, led by the University of Leicester and University Hospitals of Leicester NHS Trust, are taking place at the Leicester Royal Infirmary.

11 Aug 2009

New type of anti-clotting drug called Apixaban

The dean of the University of Oklahoma College of Public Health and a team of scientists worldwide have found a better way to prevent deadly blood clots after joint replacement surgery - a major problem that results in thousands of unnecessary deaths each year. The research appears this week in the New England Journal of Medicine.

11 Aug 2009

PTC Therapeutics achieves milestone in Schering-Plough hepatitis C collaboration

PTC Therapeutics, Inc. (PTC) today announced that it has reached a major research milestone in its collaboration with Schering-Plough Corporation (NYSE: SGP) receiving a $2 million payment in connection with the designation of a development candidate for the treatment of hepatitis C virus (HCV) infection.

11 Aug 2009

Upstream Biosciences actively seeking licensors or acquirers for anti-parasitic drug discovery portfolio and cancer diagnostic platform

Upstream Biosciences Inc. (OTCBB: UPBS) has announced that the company is actively seeking licensors or acquirers for its novel anti-parasitic drug discovery portfolio and cancer diagnostic platform.

11 Aug 2009

Pharmaceutical News

Mylan Pharmaceuticals receives final FDA report on Morgantown, W.Va., manufacturing facility

CVS Caremark announces results of 2009 Health IQ study

Sigma-Aldrich offers customizable synthetic extracellular matrix (ECM) for stem cell research

Stanford researchers want FDA to require drug makers to state how new medications compare with similar, existing treatments

Dynavax announces European development strategy for investigational adult hepatitis B vaccine in Europe

Bristol-Myers Squibb announces Hart-Scott-Rodino Review period for Medarex acquisition expired

Nanoviricides herpes study discussed on CBS News report

Health Canada approves Multaq (Dronedarone) for atrial fibrillation

Forest Labs and Astrazeneca to co-develop and commercialize ceftaroline

Providers, patients in States face budget squeeze

Schering-Plough announces agreement with Orchid Chemicals & Pharmaceuticals on generic forms of CLARINEX

Ranbaxy receives approval to market Sumatriptan Succinate tablets

Scientists discover how new drug kills roundworms

Labopharm submits response to FDA for formulation of the antidepressant trazodone

Teva announces approval of Oxaliplatin injection

Hospira launches generic version of Sanofi-Aventis' Eloxatin

Britain's first swine flu vaccine trials start

New type of anti-clotting drug called Apixaban

PTC Therapeutics achieves milestone in Schering-Plough hepatitis C collaboration

Upstream Biosciences actively seeking licensors or acquirers for anti-parasitic drug discovery portfolio and cancer diagnostic platform

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News